Hims & Hers Health shows 50% revenue growth, $1B in cash, and 2.4x 2026 sales with strong personalization and GLP-1 sales.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2.2% in the morning session after Morgan Stanley reiterated ...

Hims & Hers is down 30% but still a Buy: margin expansion, GLP-1 clarity, new hormone care, and global growth. Learn more about HIMS stock here.

Hims & Hers stock has nosedived in the past few months. It has dived by over 56% from its highest point in July last year and ...

Hims & Hers and Tempus AI are transforming digital health in distinct ways, but which platform looks more compelling right ...

Hims & Hers Health, Inc. (HIMS) closed at $28.89 in the latest trading session, marking a -5.19% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 1.16% for the ...

The equity of digital health company Hims & Hers is encountering significant downward pressure, with a confluence of technical signals, heightened short interest, and institutional selling painting a ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses lately. The San Francisco, CA-based ...

Add Yahoo as a preferred source to see more of our stories on Google. The New York Stock Exchange with a Hims & Hers Health, Inc banner is pictured as a person runs past in the Manhattan borough of ...

Hims & Hers is disrupting the healthcare industry, testing the limits of regulation to make it easier for people to buy popular drugs at lower prices online. This week, the telehealth company faced ...

The research, conducted by Talker Research on behalf of Hims, Inc., shows those expenses stretch across everyday life, from ...